Inhibrx Biosciences to Present Phase 1 Data on Ozekibart for Ewing Sarcoma at ESMO Congress
Event summary
- Inhibrx Biosciences will present Phase 1 data on ozekibart (INBRX-109) combined with irinotecan and temozolomide for Ewing Sarcoma at the ESMO Congress on March 12, 2026.
- The presentation, titled 'Phase 1 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart Combined With Irinotecan and Temozolomide in Adolescents and Adults With Ewing Sarcoma,' will be led by Rashmi Chugh, M.D., with Ana Sebio, M.D., Ph.D., as the presenting author.
- Inhibrx Biosciences was incorporated in January 2024 as a wholly-owned subsidiary of Inhibrx, Inc., following restructuring transactions and a distribution of 92% of its shares to shareholders.
The big picture
Inhibrx Biosciences' presentation at the ESMO Sarcoma and Rare Cancers Congress highlights its focus on developing novel biologic therapeutics for rare cancers. The company's proprietary protein engineering platforms aim to optimize agonist function, positioning it in a competitive landscape of targeted cancer therapies. The strategic restructuring and spin-off from Inhibrx, Inc., along with the sale of the INBRX-101 program to Sanofi S.A., underscore its focus on advancing its remaining pipeline.
What we're watching
- Clinical Efficacy
- How the Phase 1 data on ozekibart's combination therapy will impact its development trajectory and potential regulatory approval.
- Market Positioning
- Whether Inhibrx Biosciences can leverage this presentation to attract partnerships or investment for its pipeline.
- Pipeline Progress
- The pace at which Inhibrx Biosciences advances ozekibart and INBRX-106 through clinical trials following the ESMO Congress.
Related topics